| http://www.w3.org/ns/prov#value | - Pulmatrix Demonstrates Superiority of in Delivering An Effective Multi-Drug Inhaled Dose Compared to Conventional Formulation Symphogen A/S Presents Positive Rozrolimupab (SYM001) Phase 2 Trial Results in ITP at American Society of Hematology Pulmatrix's PUR118 Demonstrates Potential to Reduce Acute Exacerbations of the Lung Associated with Progressive Respiratory Diseases, such as COPD, Asthma, C
|
